Patent · US Active

Formulation for inhibiting formation of 5-HT2B agonists and methods of using same

US11759440B2 · kind B2 · utility

2Cited by

65References

10Claims

0Family size

Assignee

Zogenix International Limited · GB

Inventors

Stephen J. Farr · Orinda, US
Brooks Boyd · Berkeley, US

Key dates

Filing date	Jul 1, 2021
Grant date	Sep 19, 2023
Priority date	—
Expiry date	Jan 30, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.